AU Patent

AU2013202963B2 — Antineoplastic Combinations Containing HKI-272 and Vinorelbine

Assigned to Wyeth LLC · Expires 2016-05-12 · 10y expired

What this patent protects

ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is disclosed. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast canc…

USPTO Abstract

ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is disclosed. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013202963B2
Jurisdiction
AU
Classification
—
Expires
2016-05-12
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.